SET Nuclear Oncogene (SET) Peptide
SET
Reactivité: Humain
Hôte: Lapin
BP
N° du produit ABIN2764137
-15% Promotion 2026
199,38 €
Économisez 35,18 € (-15 %)
Plus frais de livraison 40,00 € et TVA
50 μg
Destination:
France
Envoi sous 8 à 11 jours ouvrables
Aperçu rapide pour SET Nuclear Oncogene (SET) Peptide (ABIN2764137)
Antigène
SET/TAF-I (SET)
(SET Nuclear Oncogene (SET))
Origine
Humain
Source
Lapin
Application
Blocking Peptide (BP)
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Stock
- -20 °C
-
-
- SET/TAF-I (SET) (SET Nuclear Oncogene (SET))
-
Sujet
- Human SET was originally identified as part of the SET-CAN fusion gene produced by a somatic translocation event in a patient with acute undifferentiated leukemia. In developing kidney, SET is highly expressed in the zone of nephron morphogenesis. SET has been shown to be a potent and specific inhibitor of protein phosphatase 2A, a family of major serine/threonine phosphatases involved in regulating cell proliferation and differentiation. SET is also involved in the regulation of renal cell proliferation and tumorigenesis. SET mRNA expression is markedly reduced in cells rendered quiescent by serum starvation, contact inhibition, or differentiation. SET protein expression is also much greater in developing rat and human kidney than in fully differentiated, mature kidney. High levels of SET mRNA and SET protein expression arefound in Wilms' tumor, but not in renal cell carcinoma, adult polycystic kidney disease or in transitional cell carcinoma.
Antigène
-
Vous êtes ici:
